Drug Trial Radar · NCT06644768
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Last checked: Nov 19, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
137
Planned (sponsor's estimate)
Start
Oct 30, 2024
Primary completion
Mar 30, 2028
Study completion Apr 30, 2030
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Oct 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will compare Valemetostat Tosylate Plus Pembrolizumab vs Pembrolizumab Alone in First-line NSCLC Without Actionable Genomic Alterations
Conditions
- Non-small Cell Lung Cancer
- Lung Cancer
Interventions
valemetostat tosylateDrug
Valemetostat will be administered orally once daily until RP2D of valemetostat is determined.
pembrolizumabDrug
One IV infusion Q3W on D1 of each 21-day cycle for a maximum of 35 cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1b: Number of Participants with Dose-Limiting ToxicitiesTime frame: From day of first dose on Day 1 to Day 21 in Cycle 1 (21 days), or before the administration of Cycle 2, up to 24 days
- Phase 1b: Number of Participants with Treatment-Emergent Adverse EventsTime frame: From date of first dose to 30 days after last dose, up to approximately 31 months
- Phase 2: Progression-Free Survival by BICRTime frame: From date of randomization to the date of radiographic disease progression, or death from any cause, whichever occurs first, up to approximately 31 months
Locations
35 sites in 5 countries. Site status is shown where the registry gives one.
University of California San Diego (Ucsd)-Moores Cancer Center
La Jolla, California
California Research Institute
Los Angeles, California
Valkyrie Clinical Trials
Los Angeles, California
Mayo Clinic Hospital
Jacksonville, Florida
BRCR Global
Plantation, Florida
University of Kentucky Medical Center
Lexington, Kentucky
Pikeville Medical Center
Pikeville, Kentucky
Mayo Clinic - Rochester
Rochester, Minnesota
Columbia University Irving Medical Center
New York, New York
Thomas Jefferson University, Sidney Kimmel Cancer Center
Philadelphia, Pennsylvania
Virginia Cancer Specialist
Fairfax, Virginia
Hospital Italiano de Buenos Aires
Buenos Aires, Argentina
Instituto Alexander Fleming
Buenos Aires, Argentina
Sanatorio Allende
Córdoba, Argentina
Fundacion Ars Medica
N Salvador de Jujuy, Argentina
Instituto Medico de La Fundacion Estudios Clinicos
Rosario, Argentina
Clinica Viedma S.A.
Viedma, Argentina
Centro de Pesquisas Clinica Reichow
Blumenau, Brazil
Clínica de Neoplasias Litoral Ltda.
ItajaĂ-, Brazil
CINPAM Centro Integrado De Pesquisa Da Amazonia
Manaus, Brazil
Liga Norte-Rio-Grandense Contra o Câncer
Natal, Brazil
Hospital Nossa Senhora da Conceicao
Porto Alegre, Brazil
Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto
Sao Jose Rio Preto, Brazil
Jilin Cancer Hospital
Changchun, China
Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
Hangzhou, China
Harbin Medical University Cancer Hospital
Harbin, China
Jiamusi Cancer Hospital
Jiamusi, China
Shanghai East Hospital
Shanghai, China
Tianjin Medical University Cancer Institute & Hospital
Tiyuan, China
Henan Cancer Hospital
Zhengzhou, China
Kyushu University Hospital
Fukuoka, Japan
National Cancer Center Hospital East
Kashiwa, Japan
Cancer Institute Hospital of JFCR
Kōtoku, Japan
NHO Nagoya Medical Center
Nagoya, Japan
Kitasato University Hospital
Sagamihara-shi, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.